S A Gandolfi1, L Cimino. 1. Glaucoma Research and Care Center, University of Parma, Italy. s.gandolfi@rsadvnet.it
Abstract
PURPOSE: Beta-blockers have been used since the late 1970's as 'first-choice' in the treatment for glaucoma. Since the introduction of new molecules in clinical routine, the current role of beta-blockers in glaucoma therapy has been rediscussed. In particular, concerns have been raised regarding their actual safety profile. METHODS: This review will focus on the latest advances on the efficacy and safety profiles of non-selective beta-blockers. CONCLUSIONS: The data provided will help to trace a more appropriate role for beta-blockers in glaucoma therapy.
PURPOSE: Beta-blockers have been used since the late 1970's as 'first-choice' in the treatment for glaucoma. Since the introduction of new molecules in clinical routine, the current role of beta-blockers in glaucoma therapy has been rediscussed. In particular, concerns have been raised regarding their actual safety profile. METHODS: This review will focus on the latest advances on the efficacy and safety profiles of non-selective beta-blockers. CONCLUSIONS: The data provided will help to trace a more appropriate role for beta-blockers in glaucoma therapy.